Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

40.86 -0.49 (-1.19%)
Streaming Delayed Price Updated: 3:25 PM EDT, Aug 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,329
Open 41.11
Bid (Size) 40.84 (1)
Ask (Size) 40.93 (2)
Prev. Close 41.35
Today's Range 40.08 - 41.11
52wk Range 16.45 - 62.21
Shares Outstanding 65,401,228
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-2.55%
-2.55%
1 Month
+2.87%
+2.87%
3 Month
+7.70%
+7.70%
6 Month
-14.27%
-14.27%
1 Year
+112.48%
+112.48%

More News

Read More
$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
Via InvestorPlace
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
Via Benzinga
BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024
Via InvestorPlace
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Via Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Biohaven Stock Wednesday?
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
Via InvestorPlace
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
Via InvestorPlace
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Via Benzinga
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/8
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/4
Via Investor Brand Network
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.